
Avantect Pancreatic Cancer Test Cost-Effective for High-Risk Diabetes Patients
ClearNote Health, focused on early cancer detection, has announced findings from a cost-effectiveness analysis of the Avantect Pancreatic Cancer test for managing new-onset diabetes (NOD) patients. This analysis, conducted with…












